Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1998-5-21
|
| pubmed:abstractText |
Within a prospective study we analyzed hematopoietic chimerism in serial peripheral blood samples taken from 55 patients with acute leukemias (ALL 21, AML 20, MDS 14) with a median age of 13.5 years at very short time intervals following allogeneic bone marrow transplantation (allo-BMT). The investigation was performed to determine the implications of mixed hematopoietic chimerism (MC) with regard to the clinical outcome in patients with acute leukemias after allo-BMT. Analysis of chimerism was performed by PCR of variable number of tandem repeat (VNTR) sequences with a maximum sensitivity of 0.8%. Thirteen male patients transplanted with the marrow of a female donor were also studied by amplification of a Y-chromosome-specific alphoid repeat (0.1-0.01% sensitivity). VNTR analysis in 55 patients revealed complete chimerism (CC) in 36 cases, MC in 18 follow-ups and autologous recovery in one patient. Quantitative analysis of MC identified 10/18 patients with increasing autologous patterns in whom 9/10 subsequently relapsed. The patient with autologous recovery relapsed as well. Eight of 18 patients with MC showed decreasing amounts of autologous DNA and became CC upon further follow-up. In contrast, only 7/36 patients with CC in the prior analysis of chimerism status relapsed. However, in 4/7 patients the interval between last CC confirmation and relapse was more than 4 months. In 2/7 patients autologous DNA was not detectable in peripheral blood but in bone marrow aspirates. One of these seven patients developed a fulminant relapse within 3 weeks. The probability of relapse-free survival for patients with CC is 0.67 (n = 36), for patients with decreasing MC 1.0 (n = 8) and for patients with increasing MC 0.1 (n = 10). In summary, the results demonstrate that serial and quantitative chimerism analysis at short time intervals by PCR provides a reliable and rapid screening method for the early detection of recurrence of underlying disease and is therefore a prognostic tool to identify patients at highest risk of relapse.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:BaderPP,
pubmed-author:BeckJJ,
pubmed-author:BendaNN,
pubmed-author:EinseleHH,
pubmed-author:FaulCC,
pubmed-author:FreyAA,
pubmed-author:HandgretingerRR,
pubmed-author:HebarthHH,
pubmed-author:KanzLL,
pubmed-author:KlingebielTT,
pubmed-author:NiemeyerCC,
pubmed-author:NiethammerDD,
pubmed-author:SchlegelP GPG
|
| pubmed:issnType |
Print
|
| pubmed:volume |
21
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
487-95
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9535041-Acute Disease,
pubmed-meshheading:9535041-Adolescent,
pubmed-meshheading:9535041-Adult,
pubmed-meshheading:9535041-Bone Marrow Transplantation,
pubmed-meshheading:9535041-Female,
pubmed-meshheading:9535041-Genetic Markers,
pubmed-meshheading:9535041-Graft vs Host Disease,
pubmed-meshheading:9535041-Hematopoietic Stem Cells,
pubmed-meshheading:9535041-Humans,
pubmed-meshheading:9535041-Leukemia,
pubmed-meshheading:9535041-Leukemia, Myeloid, Acute,
pubmed-meshheading:9535041-Male,
pubmed-meshheading:9535041-Minisatellite Repeats,
pubmed-meshheading:9535041-Myelodysplastic Syndromes,
pubmed-meshheading:9535041-Polymerase Chain Reaction,
pubmed-meshheading:9535041-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:9535041-Prospective Studies,
pubmed-meshheading:9535041-Recurrence,
pubmed-meshheading:9535041-Transplantation Chimera,
pubmed-meshheading:9535041-Y Chromosome
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
|
| pubmed:affiliation |
Department of Pediatric Hematology/Oncology, University Children's Hospital, Tübingen, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|